Home Companies Catalysts Deep Dives
Olumiant baricitinib APPROVED
Drug Profile
ModalitySmall molecule
RouteORAL
Therapy AreaImmunology
Launch2017-02-13
US LOE2029-01-01
Peak Sales Est$2500M
Formulations[{"id":"olumiant-oral","doses":"1mg, 2mg, 4mg","route":"ORAL","setting":"PATIENT_SELF","duration":"C
Companies
INCY (ORIGINATOR)0%
LLY (LICENSEE)100%
Mechanism: JAK inhibitor
Expert: Janus kinase inhibitor that blocks JAK1/JAK2 signaling, inhibiting cytokine-driven inflammatory cascades. Oral small molecule alternative to biologics for autoimmune diseases.
Everyday: Blocks signals inside immune cells that cause inflammation. Used for arthritis and other autoimmune conditions.
Targets: ["JAK"]
Revenue History
PeriodRevenue ($M)
Q3 2024$350M
2024$1,400M
Programs (3)
IndicationStageKey StudyRegional Status
RAAPPROVEDRA-BUILD/RA-BEAM[{"stage":"APPROVED","region":"US","label_notes":"2mg dose only in US","approval
ADAPPROVEDBREEZE-AD[{"stage":"APPROVED","region":"US","approval_date":"2022-06-15"},{"stage":"APPRO
AAAPPROVEDBRAVE-AA[{"stage":"APPROVED","region":"US","approval_date":"2022-06-13"},{"stage":"APPRO
Notes
JAK1/JAK2 inhibitor. Approved for RA, AD, alopecia areata. Licensed from Incyte.
Data from Supabase · Updated 2026-03-24